Phaseline

Companies › Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)

Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Meropenem-Vaborbactam
Beta-lactam antibiotic combined with a beta-lactamase inhibitor; meropenem is a carbapenem
DDAH1Phase 2Acute PyelonephritisJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06672978Meropenem-VaborbactamPhase 2Acute PyelonephritisInfectious diseaseJan 2027

Targets

DDAH1 (1)

Companies with the same targets

–

Companies built like this

Amplexd Therapeutics Sano Chemicals Hyundai Bioscience KTH Biopharma Frantz Viral Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.